Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $25.1 million.

  • Veracyte's Other Operating Expenses rose 591.29% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.0 million, marking a year-over-year decrease of 500.11%. This contributed to the annual value of $102.1 million for FY2024, which is 4062.11% down from last year.
  • Veracyte's Other Operating Expenses amounted to $25.1 million in Q3 2025, which was up 591.29% from $46.4 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Other Operating Expenses ranged from a high of $59.8 million in Q3 2023 and a low of -$64.6 million during Q4 2022
  • Over the past 5 years, Veracyte's median Other Operating Expenses value was $40.9 million (recorded in 2021), while the average stood at $35.3 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first tumbled by 22781.4% in 2022, then skyrocketed by 18946.98% in 2023.
  • Veracyte's Other Operating Expenses (Quarter) stood at $50.6 million in 2021, then plummeted by 227.81% to -$64.6 million in 2022, then skyrocketed by 189.47% to $57.8 million in 2023, then plummeted by 50.93% to $28.4 million in 2024, then fell by 11.63% to $25.1 million in 2025.
  • Its Other Operating Expenses was $25.1 million in Q3 2025, compared to $46.4 million in Q2 2025 and $25.1 million in Q1 2025.